ONCY - オンコリティクス・バイオテック （Oncolytics Biotech Inc.） オンコリティクス・バイオテックONCYのチャート
ONCYの企業情報
| symbol | ONCY |
|---|---|
| 会社名 | Oncolytics Biotech Inc （オンコリティクス・バイオテック） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 オンコリティクス・バイオテク(Oncolytics Biotech Inc)は開発ステージ企業である。同社はガン治療に使用されるREOLYSINの開発を中心として研究・開発に取り組む。REOLYSINはレオウイルスから開発される。このウイルスはラス(Ras)経路が活性化されている癌細胞などで増殖すると証明された。同社は人用薬品としてのREOLYSINの開発に集中する臨床試験プログラムを運営している。この臨床試験プログラムは同社が直接に出資する臨床試験とほかの機関が出資する第三者臨床試験を含む。平成23年12月31日現在、米国立がん研究所（NCI）、リーズ大学及びサンアントニオに位置するテキサス大学ヘルスセンターのがん治療・研究センターは同社臨床試験プログラムに部分的に出資した。同社は委託製造者を通じてREOLYSINを生産する。 オンコリティクス・バイオテックはカナダの医薬品メ―カ―。従来の治療法が有効でないがん治療薬の発見と開発に従事。候補薬｢REOLYSIN｣の開発を手掛ける。同社が開発した治療薬は従来の化学療法、放射線治療、外科的切除などの補助療法としても使用される。本社はカナダのアルバ―タ州。 oncolytics biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. the company is conducting clinical studies using reolysin®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. oncolytics’ clinical program includes a number of human trials at a variety of stages including a phase iii trial in head and neck cancers. the company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product. |
| 本社所在地 | Suite 210 1167 Kensington Crescent N.W. Calgary Alberta T2N 1X7 CAN |
| 代表者氏名 | Wayne F. Pisano ウェインF.ピサノ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 403-670-7380 |
| 設立年月日 | 35886 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.oncolytics.ca |
| nasdaq_url | https://www.nasdaq.com/symbol/oncy |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.42731 |
| 終値（lastsale） | 3.68 |
| 時価総額（marketcap） | 62176293.76 |
| 時価総額 | 時価総額（百万ドル） 53.40790 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 39.09825 |
| 当期純利益 | 当期純利益（百万ドル） -12.69917 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Oncolytics Biotech Inc. (USA) revenues was not reported. Net loss increased 13% to C$8.9M. Higher net loss reflects Other Operating Expense increase of 17% to C$2.8M (expense) Stock-based Compensation in R&D increase from C$126K to C$331K (expense) Stock-based Compensation in SGA increase from C$163K to C$366K (expense). |
ONCYのテクニカル分析
ONCYのニュース
Maxim Group maintains Oncolytics Biotech at ''buy'' with a price target of $5.00 2023/06/05 16:26:37 Investing.com
https://www.investing.com/news/pro/oncolytics-biotec-receives-investment-bank-analyst-rating-update-3098457
Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate 2023/06/05 12:00:05 FinancialNewsMedia
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with paclitaxel monotherapy 12-month progression-free survival rate of 32.8% for pelareorep-paclitaxel compared to 0% for paclitaxel monotherapy and 0% for pelareorep-paclitaxel-avelumab Oncolytics’ HR+/HER2- breast cancer program now phase 3-ready […] The post Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate appeared first on Financial News Media .
Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate 2023/06/05 11:06:00 Finanz Nachrichten
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclita…
Oncolytics Biotech Reports Updated Data from BRACELET-1 Trial that Show Pelareorep Delivered Increases in Progression-Free Survival 2023/06/05 11:04:01 Investing.com
https://www.investing.com/news/assorted/oncolytics-biotech-reports-updated-data-from-bracelet1-trial-that-show-pelareorep-delivered-increases-in-progressionfree-survival-432SI-3098144
Oncolytics Biotech Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate 2023/06/05 11:00:00 PR Newswire
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with paclitaxel monotherapy 12-month progression-free survival rate of 32.8%…
Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting 2023/04/26 14:48:00 Finanz Nachrichten
Oral presentation on BRACELET-1 to take place on June 3, 2023 SAN DIEGO and CALGARY, AB, April 26, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the accep…
Oncolytics Biotech® Inc.: Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity''s Horizons in Oncology Virtual Conference 2023/04/12 11:30:00 Finanz Nachrichten
SAN DIEGO and CALGARY, AB, April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Medical Officer Thomas Heineman, M.D., Ph.D., will participa…
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity''s Horizons in Oncology Virtual Conference 2023/04/12 11:23:00 Benzinga
SAN DIEGO and CALGARY, AB , April 12, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY ) (TSX: ONC ) today announced that Chief Medical Officer Thomas Heineman , M.D., Ph.D., will participate in the Viral Immunotherapy – Moving Forward panel at Canaccord Genuity''s Horizons in Oncology Virtual Conference, which is taking place virtually on April 20, 2023 . Additional details on the panel presentation can be found below. … Full story available on Benzinga.com
Oncolytics Biotech® Inc.: Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights 2023/04/12 11:06:00 Finanz Nachrichten
Conference call and webcast to take place on Friday, May 5, 2023, at 8:30 a.m. ET SAN DIEGO and CALGARY, AB, April 12, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today…
Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders 2023/04/12 10:48:00 Finanz Nachrichten
Your vote is important no matter how many votes you hold. Vote today Shareholders who have questions or need assistance with voting their shares should contact Oncolytics Biotech Inc.''s strategic …
Oncolytics Biotech Inc.: Oncolytics Biotech Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting 2022/10/05 12:10:00 Finanz Nachrichten
Interim results from the phase 1/2 GOBLET study''s pancreatic cancer cohort to be presented in a poster on November 11th and discussed during a key opinion leader webinar on November 14th at 10 a.m…
Oncolytics Biotech Inc.: Oncolytics Biotech Appoints Jonathan Rigby to its Board of Directors 2022/09/07 11:04:00 Finanz Nachrichten
Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO and CALGARY, AB, Sept. 7, …
RBC Capital Reiterates Outperform Rating on Oncolytics Biotech 2022/08/22 16:48:02 Investing.com
https://www.investing.com/news/pro/rbc-capital-reiterates-outperform-rating-on-oncolytics-biotech-432SI-2877592
Oncolytics Biotech Inc. (ONCY) CEO Matthew Coffey on Q2 2022 Results - Earnings Call Transcript 2022/08/11 20:21:09 Seeking Alpha
Oncolytics Biotech Inc. (NASDAQ:NASDAQ:ONCY) Q2 2022 Results Conference Call August 11, 2022 08:30 AM ET Company Participants Jon Patton - Director of Investor Relations and Communications…
Oncolytics Biotech Inc.: Oncolytics Biotech Reports Second Quarter 2022 Financial Results and Recent Operational Highlights 2022/08/11 11:04:00 Finanz Nachrichten
Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in HR+/HER2- breast cancer Achieved success …